Abstract Details

Title Review of Dispensing Data and Patient Reported Outcome Measures (PROMs) in Myasthenia Gravis (MG) and Lambert-Eaton Syndrome (LES) Patients Prescribed Immunoglobulin (Ig) and Eculizumab by a Specialty Infusion Pharmacy Using SoleMetricsTM

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 099

Objective

To analyze myasthenia gravis (MG) and Lambert-Eaton syndrome (LES) dispensing records and patient-reported outcome measures (PROMs) for patients receiving intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and eculizumab through a specialty infusion pharmacy.

Background The Myasthenia Gravis Quality of Life (MG-QOL15) scale is a validated tool that efficiently assesses QOL in patients with MG. PROMs, like the MG-QOL15, are utilized by providers and payors to determine the benefit of ongoing therapy in MG and LES. Specialty infusion organizations have frequent contact with MG patients and are poised to collect PROMs data.

Design/Methods A retrospective analysis of dispensing records and PROMs from a proprietary clinical outcomes program, SoleMetrics^TM, was conducted, including patients who had LES (G70.80) and MG with/without acute exacerbation (G70.01, G70.00). Medications analyzed were IVIg, SCIg, and eculizumab. The review also included patient demographics, number of prescribing physicians, total number of dispenses, and mean values from MGQOL-15 and an internal QOL measurement [Soleo Wellness (SW)].

Results 496 patients met the criteria: 9 (G70.80), 234 (G70.01), and 254 (G70.00). Demographic mean values: Gender 58% female, age 61, weight 86.64 kg. Total number of unique providers: 396. Total number of dispenses: 32,027 (25,310 IVIg, 1,563 SCIg, and 5,154 eculizumab). Number of completed PROMs: 4,267 SoleMetrics^TM assessments, 3,446 MG-QOL15, and 3,425 SW. Mean number of PROMs per patient and corresponding mean values: 12 MG-QOL15 (13) and 11 SW (3).

Conclusions SoleMetrics^TM allows the collection of information not readily available to treating physicians between routine office visits and Ig/eculizumab administration, including symptom management, therapy optimization, adverse events, and PROMs. By reviewing SoleMetrics^TM data, providers may be able to optimize therapy and clinical outcomes in patients with MG and LES. Other PROMs in the process of being collected and analyzed in future publications include pain, Myasthenia Gravis Activities of Daily Living (MG-ADL), and Modified Rasch-built Fatigue Severity Scale (mfSS).

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Christine Miller (Soleo Health)	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details